The thesis

Tempus AI operates a data-driven oncology and diagnostics platform that connects clinical workflows with multimodal patient data. The conviction score sits at 56 out of 100 — not a strong signal. Revenue growth is reported at negative 520% year over year, a figure that points to severe accounting or restatement distortion, not organic expansion. Net margin is negative 2,220% and the DCF model produces a negative intrinsic value of $150, meaning discounted cash flows do not support any positive equity value at current burn rates. Analyst consensus is buy, but that consensus is running directly against what the fundamentals show — that gap is the central tension here.

Why now

A risk-off rotation is actively repricing speculative growth names, and Tempus AI sits squarely in that crossfire as a pre-profit, high-multiple healthcare technology company. A potential Federal Reserve rate increase in as few as six weeks, flagged by a JPMorgan executive citing incoming Fed Chair Kevin Warsh, would further compress the long-duration multiple that this stock depends on.

What to watch

Watch gross margin trajectory over the next two quarters — any improvement toward a sustainable positive range would be the first hard evidence that the platform economics can eventually support the valuation. Monitor whether the company accesses capital markets through equity issuance or debt, which would signal burn rate stress and likely trigger further dilution.

Key risks

The DCF produces a negative intrinsic value, meaning the market price is entirely a function of narrative and sentiment, not cash flow — any narrative disruption collapses the floor. The negative 2,220% net margin means the company is consuming capital at a rate that demands either continued dilutive financing or a dramatic and unproven operational turnaround. Rising rates directly punish this profile: higher discount rates destroy the present value of distant, uncertain cash flows that make up the entire bull case.